Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agyster is a digestive enzyme combination product developed and marketed by Aganit Pharma. It contains fungal diastase and papain, which serve as exogenous enzymes to facilitate the breakdown of complex nutrients in the gastrointestinal tract. Fungal diastase, an amylolytic enzyme derived from *Aspergillus oryzae*, assists in the digestion of carbohydrates by converting starch into simpler sugars like maltose. Papain, a proteolytic enzyme extracted from the fruit of the papaya (*Carica papaya*), aids in the digestion of proteins by cleaving peptide bonds. The formulation is primarily indicated for the relief of symptoms associated with digestive insufficiency, such as dyspepsia, bloating, and flatulence, where endogenous enzyme production may be inadequate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Agyster.